Discover

ICLR
ICON Public Limited Company
114.19
8 x 112.54
8 x 116.08
bid
ask
+
2.77
2.49%
8 @ 04:00 PM
114.17 -0.02 (0.02%)
Ytd -37.33%
1y -32.31%
108.58
day range
115.63
80.08
52 week range
202.92
Open 110.06 Prev Close 111.42 Low 108.58 High 115.63 Mkt Cap 8.88B
Vol 651.38K Avg Vol 1.85M EPS 7.42 P/E 15.39 Forward P/E 9.13
Beta 1.34 Short Ratio 0.88 Inst. Own 109.97% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-16 50-d Avg 122.47 200-d Avg 159.88 1yr Est 134.69
Earning
Date For Estimate Reported Surprise surprise %
2026-04-29 2026-03 3.1 N/A N/A N/A
2026-04-01 2025-12 3.3 N/A N/A N/A
2025-10-22 2025-09 3.28 2.83 -0.45 -13.72%
2025-10-22 2025-09 3.28 3.31 0.03 0.91%
2025-07-23 2025-06 3.18 3.26 0.08 2.52%
2025-07-23 2025-06 3.18 3.16 -0.02 -0.63%
Upgrade / Downgrade
Date Firm Action From To
2026-03-26 BMO Capital Upgrade Market Perform Outperform
2026-03-11 Citigroup Upgrade Neutral Neutral
2026-03-09 Barclays Upgrade Equal-Weight Equal-Weight
2026-02-23 Jefferies Upgrade Hold Buy
2026-02-18 TD Cowen Upgrade Hold Buy
2026-01-22 TD Cowen Upgrade Hold Hold
Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Artisan Partners Limited Partnership 6.87M 784.94M 8.51%
2025-12-30 Wellington Management Group, LLP 4.35M 496.81M 5.39%
2025-12-30 Orbis Allan Gray Ltd 4.21M 481.27M 5.22%
2025-12-30 Invesco Ltd. 3.76M 429.00M 4.65%
2025-12-30 FMR, LLC 3.10M 353.75M 3.84%
2025-12-30 Principal Financial Group, Inc. 3.00M 342.75M 3.72%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 Artisan Partners Funds Inc.-Artisan International Value Fund 5.17M 590.36M 6.40%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 1.21M 138.61M 1.50%
2025-12-30 NEW PERSPECTIVE FUND 1.06M 120.98M 1.31%
2025-12-30 HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund 1.05M 119.79M 1.30%
2026-01-30 VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund 999.22K 114.10M 1.24%
2026-01-30 AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND 975.20K 111.36M 1.21%
Split
Split Date
2 : 1 2008-08-13
2 : 1 2006-10-24